Cargando…

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

OBJECTIVE: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Twenty patients (aged 7–78 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gattorno, Marco, Obici, Laura, Cattalini, Marco, Tormey, Vincent, Abrams, Ken, Davis, Nicole, Speziale, Antonio, Bhansali, Suraj G, Martini, Alberto, Lachmann, Helen J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264215/ https://www.ncbi.nlm.nih.gov/pubmed/27269295 http://dx.doi.org/10.1136/annrheumdis-2015-209031

Ejemplares similares

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study
por: Lachmann, H, et al.
Publicado: (2015)

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome
por: Torene, Rebecca, et al.
Publicado: (2017)

Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps
por: Gattorno, M, et al.
Publicado: (2014)

The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry
por: Lachmann, H J, et al.
Publicado: (2014)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

PW02-008 - TRAPS in the real world: an international registry
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
por: Papa, Riccardo, et al.
Publicado: (2020)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

PW02-021 - SAA1 is the strongest predictor of AA in TRAPS
por: Obici, L, et al.
Publicado: (2013)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
por: Aróstegui, JI, et al.
Publicado: (2015)

OR10-005 - Treatment responses in TRAPS: Eurofever/ Eurotraps
por: Lachmann, HJ, et al.
Publicado: (2013)

Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes
por: Piram, Maryam, et al.
Publicado: (2014)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
por: Ruperto, Nicolino, et al.
Publicado: (2018)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
por: Schlesinger, Naomi, et al.
Publicado: (2011)

Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives
por: Cudrici, Cornelia, et al.
Publicado: (2020)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network
por: Gaggiano, Carla, et al.
Publicado: (2020)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Somatic mosaicism in adult‐onset TNF receptor‐associated periodic syndrome (TRAPS)
por: Kontzias, Apostolos, et al.
Publicado: (2019)

How experts on autoinflammatory diseases classify inherited periodic fevers: preliminary results of the Eurofever Delphi Survey
por: Federici, S, et al.
Publicado: (2015)

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network
por: Vitale, Antonio, et al.
Publicado: (2020)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Impact of MEFV genotype in Caucasian children with periodic fever
por: Federici, Silvia, et al.
Publicado: (2011)

Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome
por: Kimberley, Fiona C, et al.
Publicado: (2007)

How experts on Autoinflammatory diseases classify Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical Adenitis (PFAPA): preliminary results of the Eurofever Delphi survey
por: Vanoni, F, et al.
Publicado: (2015)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i6ptbfqcjl6362i6h01am37ibm